Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03242642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Study acronym: APOLLO
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 86 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Study completion moved earlier from Sep 30, 2036 to Jul 7, 2036
    • Primary completion date: May 30, 2027 to Jun 2027
    • Eligibility criteria expanded, about 8 words
    • Site details revised at 12 of 85 sites
  2. Site details revised at 2 of 85 sitesv85
  3. Site details revised at 5 of 85 sitesv84
  4. Site details revised at 1 of 85 sitesv83
  5. Study sites revised (85)v82
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 3 of 85 sitesv81
  2. Site details revised at 1 of 85 sitesv80
  3. Site details revised at 3 of 85 sitesv79
  4. Site details revised at 1 of 85 sitesv78
  5. Study sites revised (85)v77
  6. Site details revised at 1 of 85 sitesv76
  7. Site details revised at 2 of 85 sitesv75
  8. Site details revised at 1 of 85 sitesv74
  9. Re-verified, no change to tracked fieldsv73
  10. Study sites revised (85)v72
  11. Site details revised at 3 of 85 sitesv71
  12. Site details revised at 1 of 85 sitesv70
  13. Primary completion date: Oct 30, 2026 to May 30, 2027
    • Site details revised at 2 of 85 sites
    v69
  14. Site details revised at 1 of 85 sitesv68
  15. Site details revised at 2 of 85 sitesv67
  16. Site contacts updated at 1 of 85 sitesv66
  17. Site details revised at 1 of 85 sitesv65
  18. Site details revised at 1 of 85 sitesv64
  19. Site details revised at 3 of 85 sitesv63
  20. Study sites revised (85)v62
  21. Study sites revised (85)v61
  22. Study sites revised (85)v60
  23. Study sites revised (85)v59
  24. Site contacts updated at 1 of 85 sitesv58
  25. Enrollment target: 1156 to 1056
    • Study completion date: Sep 30, 2035 to Sep 30, 2036
    v57
  26. Study sites: 86 to 85v56
  27. Site details revised at 1 of 86 sitesv55
  28. Site details revised at 1 of 86 sitesv54
  29. Study sites: 87 to 86v53
  30. Site details revised at 1 of 87 sitesv52
  31. Re-verified, no change to tracked fieldsv51
  32. Study sites: 85 to 87v50
  33. Enrollment target: 1350 to 1156v49
  34. Site details revised at 6 of 85 sitesv48
  35. Study sites: 84 to 85v47
  36. Study sites: 83 to 84v46
  37. Study sites: 81 to 83v45
  38. Study sites: 79 to 81v44
  39. Primary completion date: Oct 2023 to Oct 30, 2026
    • Study sites: 76 to 79
    • Study completion date: Oct 2028 to Sep 30, 2035
    v43
  40. Study sites: 74 to 76v42
  41. Study sites: 70 to 74v41
  42. Study sites revised (70)v40
  43. Study sites: 69 to 70v39
  44. Study sites: 68 to 69v38
  45. Study sites: 66 to 68v37
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Trial Details
NCT Number NCT03242642
Lead Sponsor Medtronic Cardiovascular
Conditions
(from sponsor)		 Mitral Valve Regurgitation
Related terms Cardiovascular Diseases, Heart Diseases, Heart Valve Diseases, Mitral Valve Insufficiency
Enrollment 1,056 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov